Cargando…

Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells

The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathway is a therapeutic target for various types of human tumors, and dual PI3K/mTOR inhibitors demonstrate antitumor activities in both preclinical and clinical studies. However, resistance mechanisms limit their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murase, Yusuke, Hosoya, Kenji, Sato, Takachika, Kim, Sangho, Okumura, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848474/ https://www.ncbi.nlm.nih.gov/pubmed/35088890 http://dx.doi.org/10.3892/or.2022.8272

Ejemplares similares

Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
por: Langdon, Simon P., et al.
Publicado: (2019)

Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues
por: Costa, Caroline Marques Xavier, et al.
Publicado: (2023)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
por: Wilson, George D., et al.
Publicado: (2020)

ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
por: Liu, Changfu, et al.
Publicado: (2021)

The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings
por: Shor, Ryann E., et al.
Publicado: (2021)

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
por: Wainberg, Zev A., et al.
Publicado: (2017)

Compensatory Cellular Reactions to Nonsteroidal Anti-Inflammatory Drugs on Osteogenic Differentiation in Canine Bone Marrow-Derived Mesenchymal Stem Cells
por: OH, Namgil, et al.
Publicado: (2014)

In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma
por: Pyuen, Alex A., et al.
Publicado: (2018)

Isolation and characterization of canine tumor endothelial cells
por: IZUMI, Yusuke, et al.
Publicado: (2014)

Chronological differential effects of pro-inflammatory cytokines on RANKL-induced osteoclast differentiation of canine bone marrow-derived macrophages
por: WIJEKOON, Suranji, et al.
Publicado: (2017)

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2014)

Antitumor activity of a novel dual functional podophyllotoxin derivative involved PI3K/AKT/mTOR pathway
por: Li, Yongli, et al.
Publicado: (2019)

Inhibitory effects of sodium pentosan polysulfate on formation and function of osteoclasts derived from canine bone marrow
por: Wijekoon, H. M. Suranji, et al.
Publicado: (2018)

Independent chondrogenic potential of canine bone marrow-derived mesenchymal stem cells in monolayer expansion cultures decreases in a passage-dependent pattern
por: BWALYA, Eugene C., et al.
Publicado: (2018)

Effects of pentosan polysulfate and polysulfated glycosaminoglycan on chondrogenesis of canine bone marrow-derived mesenchymal stem cells in alginate and micromass culture
por: BWALYA, Eugene C., et al.
Publicado: (2017)

In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458
por: Albawardi, Alia, et al.
Publicado: (2014)

Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
por: Sacco, Antonio, et al.
Publicado: (2010)

Pentosan polysulfate inhibits IL-1β-induced iNOS, c-Jun and HIF-1α upregulation in canine articular chondrocytes
por: Bwalya, Eugene C., et al.
Publicado: (2017)

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells
por: Wang, Jingqiu, et al.
Publicado: (2020)

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
por: Tarantelli, Chiara, et al.
Publicado: (2020)

Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
por: Kashiyama, Tomoko, et al.
Publicado: (2014)

Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
por: Kim, Hyung Joon, et al.
Publicado: (2020)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Inhibition of Survivin Influences the Biological Activities of Canine Histiocytic Sarcoma Cell Lines
por: Yamazaki, Hiroki, et al.
Publicado: (2013)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

Structural insights of a PI3K/mTOR dual inhibitor with the morpholino-triazine scaffold
por: Takeda, Takako, et al.
Publicado: (2016)

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
por: Luo, Leixuan, et al.
Publicado: (2023)

Safety and efficacy of a nonmyeloablative pretransplant conditioning regimen using total lymphoid irradiation with volumetric modulated arc therapy in healthy dogs: A pilot study
por: Kim, Sangho, et al.
Publicado: (2021)

Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity
por: Yang, Qichao, et al.
Publicado: (2022)

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells
por: Gamper, Christopher J., et al.
Publicado: (2012)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
por: Echeverry, N, et al.
Publicado: (2015)

Developing a novel dual PI3K–mTOR inhibitor from the prodrug of a metabolite
por: Zhou, Yan, et al.
Publicado: (2017)

Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors
por: Zhao, Bingbing, et al.
Publicado: (2018)

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo
por: Shi, Fei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o930vhh06j2tf5j446dcnnqaqa